Lung Cancer Therapy Annual 7

Overview

Oncology research and practice in lung cancer continues to develop rapidly. This latest edition of Lung Cancer Therapy Annual briefs the oncology community with a review of the recent literature, emphasizing the therapeutic aspects.

It offers an update of the impact that this information will have on the day-to-day management of the lung cancer patient.

New to the Seventh Edition:

• An update of the impact of recent developments will have on day-to-day management of lung cancer patients
• Four new chapters on the treatment of non-small cell lung cancer (NSCLC)
• A new chapter on thymoma

Additional topics include:

• Oncogenic driver mutations
• First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
• Second line therapy of non-small cell lung cancer
• Adjunct and neoadjunct therapy of non-small cell lung cancer
• Advances in surgery of lung cancer; advances in radiotherapy of lung cancer
• Mesothelioma
• Thymic tumors

Reviews

"This is an excellent resource for beginners as well as advanced specialists in the field. The references are current to the year 2008 and the individual chapters are brief and complete and will give readers a solid foundation in the treatment of lung cancer to build upon."
- K. P. Ravikrishnan, FRCP (C), FACP FCCP(William Beaumont Hospitals)

Contents

1. Epidemiology
2. Prevention, early detection, and screening
3. Staging
4. Histopathology and molecular pathology
5. Oncogenic driver mutations
6. First line therapy of advanced non-small cell lung cancer without activating EGFR mutation
7. First line therapy of advanced non-small cell lung cancer with activating EGFR mutation
8. Second line therapy of non-small cell lung cancer
9. Adjuvant and neoadjuvant therapy of non-small cell lung cancer
10. Advances in surgery of lung cancer
11. Advances in radiotherapy of lung cancer
12. Small cell lung cancer
13. Mesothelioma
14. Thymoma

Author

Rolf A. Stahel, M.D. is head of the Center for Lung and Thoracic Oncology and Senior Staff Physician at the Clinic of Oncology, University Hospital of Zürich as well as Titular Professor of Medicine at the University of Zürich, Switzerland. He is certified in Internal Medicine and Medical Oncology by both the American and Swiss Board. His major interest is thoracic oncology, including multidisciplinary treatment approaches, translational research and targeted therapy.

He was a founding member and the first president of the Swiss Society for Medical Oncology. He served as president of the Swiss Institute for Applied Cancer Research from 1999 to 2005. He is member of the International Association for the Study of Lung Cancer (IASLC), where he served as chair of the fellowship committee and since 2009 is a member of the board of directors. In the European Society for Medical Oncology (ESMO) he served as National Representative from 1998 to 2004 and chaired the ESMO Task Force on Guidelines from 1999 to 2005. Since 2003 he has been a member of the ESMO board of directors, and has been the chair of the ESMO Educational Committee and member of the ESMO Executive Committee since 2006 he is the chair. In addition, he is president-elect of ESMO (2012).

Professor Stahel has been president of the foundation council of the International Breast Cancer Study Group (IBCSG) since 2008, and since 2009 has been president of the European Thoracic Oncology Platform (ETOP), a foundation with the aim to bring together European collaborative groups and institutions focusing on research on thoracic malignancies.

He is editor in-chief of Lung Cancer and editor of Cancer Treatment Reviews.